Results 141 to 150 of about 22,015 (248)
Biosimilar medicines and cost-effectiveness
ClinicoEconomics and Outcomes Research, 2011 Steven SimoensResearch Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Given that biosimilars are agents that are similar but not identical to the ...
Steven Simoens
doaj
Drug Testing and Analysis, Volume 18, Issue 4, Page 537-542, April 2026.A basic EPO IEF profile was identified in patients with familial erythropoiesis linked to mutations in noncoding parts of EPO gene. Comparison of blood and urine EPO profiles from these patients differed from adult wild‐type EPO (WT) and from Eprex‐administered patients. Patients' EPO do not differ from WT EPO after analysis using SDS‐PAGE/SAR‐PAGE. It
Laurent Martin +9 more
wiley +1 more source
Open Access Rheumatology: Research and Reviews, 2017 Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O’Sullivan, Ann Maria Curran, John J Carey Department of Rheumatology, Galway University Hospitals, Galway ...
Abdalla A +8 more
doaj
Health Science Reports, Volume 9, Issue 4, April 2026.ABSTRACT Background and Aims Multiple sclerosis (MS) is an autoimmune disorder that damages the myelin sheath on nerve fibers in the central nervous system, leading to axonal damage and neuron death. This study aimed to assess the cost‐effectiveness of dimethyl fumarate compared with teriflunomide as first‐line oral medications for patients with ...
Maryam Poursadeghfard +6 more
wiley +1 more source
JGH Open, Volume 10, Issue 4, April 2026.ABSTRACT Crohn's disease (CD) is a chronic inflammatory condition of the bowel with a rising global incidence. Its complex etiology involves genetic susceptibility, environmental factors, and alterations in the gut microbiota, leading to dysregulated immune responses.
Yoon‐Kyo An +3 more
wiley +1 more source
Direct Switch From Iptacopan to Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria
eJHaem, Volume 7, Issue 2, April 2026.ABSTRACT Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal hematologic disorder treated with complement inhibitors. Currently, patients with suboptimal response to C5 inhibitors may be switched to proximal complement inhibitors, such as pegcetacoplan, danicopan, or iptacopan.
Vitalii Latyshev +3 more
wiley +1 more source
The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects [PDF]
, 2017 core +1 more source
Targeted Therapies for Each Subtype of Breast Cancer
MedComm, Volume 7, Issue 4, April 2026.This review systematically summarizes the advances in targeted therapies for the three major molecular subtypes of breast cancer (BC), highlighting key strategies, agents, and clinical progress to guide personalized treatment. HR‐positive (luminal) BC: Dominated by estrogen receptor (ER) signaling, with endocrine therapies as the cornerstone—including ...
Aiyu Liu +5 more
wiley +1 more source
Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.This review synthesizes current mechanistic and clinical evidence on IL‐6 inhibitors, particularly sarilumab and tocilizumab, concerning their effect on pain in RA. ABSTRACT Rheumatoid arthritis (RA) is an autoimmune systemic disease in which pain remains a major and often refractory symptom even after clinical remission of the disease.
Andrej Belančić +10 more
wiley +1 more source